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Background. Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens.
Methods. Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with
hospital-acquired pneumonia (HAP) due to gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus
(MRSA). Patients were randomized 1:1 to telavancin (10 mg/kg every 24 h) or vancomycin (1 g every 12 h) for 7–21 days. The
primary end point was clinical response at follow-up/test-of-cure visit.
Results. A total of 1503 patients were randomized and received study medication (the all-treated population). In the pooled all-
treated population, cure rates with telavancin versus vancomycin were 58.9% versus 59.5% (95% conﬁdence interval [CI] for the
difference, –5.6% to 4.3%). In the pooled clinically evaluable population (n 5 654), cure rates were 82.4% with telavancin and 80.7%
with vancomycin (95% CI for the difference, –4.3% to 7.7%). Treatment with telavancin achieved higher cure rates in patients with
monomicrobial S. aureus infection and comparable cure rates in patients with MRSA infection; in patients with mixed gram-positive/
gram-negative infections, cure rates were higher in the vancomycin group. Incidence and types of adverse events were comparable
between the treatment groups. Mortality rates for telavancin-treated versus vancomycin-treated patients were 21.5% versus 16.6% (95%
CI for the difference, –0.7% to 10.6%) for study 0015 and 18.5% versus 20.6% (95% CI for the difference, –7.8% to 3.5%) for study
0019. Increases in serum creatinine level were more common in the telavancin group (16% vs 10%).
Conclusions. The primary end point of the studies was met, indicating that telavancin is noninferior to vancomycin on the
basis of clinical response in the treatment of HAP due to gram-positive pathogens.
Hospital-acquired pneumonia (HAP) is the second most
common nosocomial infection and the leading cause of
mortality attributable to these critical infections [1–3].
Staphylococcus aureus, particularly methicillin-resistant
S. aureus (MRSA), is now a major cause of HAP [4–6].
Rates of clinical failure in patients with HAP due to
MRSA are high [7, 8]. Currently, only vancomycin and
linezolid are recommended for treatment of HAP due to
MRSA [9]. Resultsfromrecentpneumonia trialswithnew
antibiotics active against MRSA have not been encour-
aging [10–12]. Therefore, additional antistaphylococcal
agents for treatment of HAP are urgently needed.
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Telavancin for Gram-positive Pneumonia d CID 2011:52 (1 January) d 31Telavancin is a lipoglycopeptide antibacterial agent exhibiting
potent, concentration-dependent bactericidal effects via a dual
mechanism of actionthat combines inhibition ofcellwallsynthesis
and disruption of membrane barrier function [13–15]. In vitro,
telavancin is rapidly bactericidal against clinically important gram-
positive bacteria, including MRSA, vancomycin-intermediate
S. aureus, and penicillin-resistant S. pneumoniae [13, 16, 17].
Telavancin penetrates well into the epithelial lining ﬂuid and
alveolar macrophages of healthy subjects, achieving concen-
trationsupto8-foldand85-fold,respectively, abovetelavancin’s
minimum inhibitory concentration (MIC) for 90% (MIC90)o f
MRSA strains (.5 lg/mL) [16, 18]. Unlike daptomycin (a cyclic
lipopeptide),telavancinremainsactiveinvitrointhepresenceof
pulmonary surfactant [16]. Telavancin is approved in the
United States and Canada for the treatment of adult patients
with complicated skin and skin-structure infections due to
susceptible gram-positive pathogens.
The current studies were designed to assess the clinical efﬁ-
cacy and safety of telavancin compared with vancomycin in the
treatment of HAP due to gram-positive organisms, with a focus
on infections due to MRSA. Partial results of these studies have
been previously reported.
METHODS
The Assessment of Telavancin for Treatment of Hospital-
Acquired Pneumonia (ATTAIN) studies were 2 identical ran-
domized, double-blind, comparator-controlled, parallel-group
phase III trials, 0015 and 0019 (NCT00107952 and
NCT00124020), with patients enrolled between January 2005
and June 2007. The institutional review board at each site ap-
proved the protocol, and all patients or their authorized repre-
sentatives provided written informed consent.
Patient selection. Male and nonpregnant female patients
aged >18 years were eligible for enrollment if they had pneu-
monia acquired after 48 h in an inpatient acute or chronic care
facility or that developed within 7 days after being discharged.
Patients were required to have >2 of the following: cough,
purulent sputum, auscultatory ﬁndings, dyspnea, tachypnea, or
hypoxemia; or identiﬁcation of an organism consistent with
a respiratory pathogen isolated from respiratory tract or blood.
In addition, patients were also required to have >2 of the fol-
lowing: fever (temperature .38C) or hypothermia (rectal/core
temperature ,35C); respiratory rate .30 breaths/min; pulse
rate >120 beats/min; altered mental status; need for mechanical
ventilation; and white blood cell count .10,000 cells/mm
3,
,4500 cells/mm
3,o r.15% immature neutrophils (band
forms). All patients were required to have new or progressive
inﬁltrates, consolidation, with or without pleural effusion on
chest radiograph (or computed tomography), and an adequate
respiratory specimen for Gram stain and culture.
Patients were excluded if they had any of the following: re-
ceipt of potentially effective systemic antibiotic therapy for
gram-positive pneumonia for .24 h immediately prior to
randomization (unless there was documented clinical failure
after 3 days of therapy or if the pathogen was resistant in vitro
to previous treatment); only gram-negative bacteria seen on
Gram stain or culture; baseline QTc interval .500 msec, un-
compensated heart failure; absolute neutrophil count ,500
cells/mm
3; or pulmonary disease that precludes evaluation of
therapeutic response (eg, lung cancer, active tuberculosis, cystic
ﬁbrosis, or granulomatous disease).
Randomization and treatment regimens. The ATTAIN
trials were double-blinded studies in which patients were ran-
domized (1:1) to receive either intravenous (IV) telavancin at
a dosageof10mg/kgevery 24hor vancomycinata dosageof1 g
IV every 12 h for 7–21 days. Randomization was conducted
through an interactive voice response system using permuted
block algorithm and stratifying by country group, presence of
diabetes, and ventilatory status. The vancomycin regimen could
be monitored and adjusted according to the institutional policy
at each site but had to be performed such that blinding was not
compromised. The dose of telavancin was adjusted in patients
with creatinine clearance <50 mL/min. For patients with
pneumonia due to suspected or proven methicillin-susceptible
S. aureus (MSSA), a switch to antistaphylococcal penicillin from
vancomycin was permitted. In patients with polymicrobial
(mixed gram-positive/gram-negative) infection, concomitant
therapy with aztreonam or piperacillin-tazobactam was allowed.
Assessments. Clinical assessments were performed at base-
line and daily throughout study treatment, at the end of therapy
(EOT),andatfollow-up/testofcure visit(FU/TOC).Laboratory
assessments were performed every 3 days up to the EOT. FU/
TOC assessment was conducted 7–14 days after EOT.
Respiratory samples (invasive or noninvasive) and 2 blood
culture specimens were obtained at baseline for Gram stain
and culture [9]. Isolated pathogens were submitted to a central
laboratory for conﬁrmation of identity and susceptibility
testing [19].
Telavancinplasmasamplesforpharmacokineticanalyseswere
obtained at some centers, as were vancomycin trough levels, in
accordance with site-speciﬁc procedures.
Efﬁcacy and safety variables. Clinical responses at FU/
TOC were deﬁned as follows. Cure was deﬁned as improvement
or lack of progression of baseline radiographic ﬁndings at EOT
and resolution of signs and symptoms of pneumonia at FU/
TOC. Failure was deﬁned as persistence or progression of signs
and symptoms or progression of radiological signs of pneu-
monia at EOT; termination of study medications due to ‘‘lack of
efﬁcacy’’ and initiation within 2 calendar days of a different
potentially effective antistaphylococcal medication; death on or
after day 3 attributable to primary infection; or relapsed
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determinate response was deﬁned as the inability to determine
outcome. Adverse events (AEs), vital signs, electrocardiograms,
and laboratory parameters were also evaluated.
Analysis populations. The all-treated (AT) population in-
cluded all randomized patients who received >1 dose of study
medication. The modiﬁed all-treated (MAT) population con-
sisted of patients in the AT population who had a respiratory
pathogen identiﬁed from baseline samples (or from blood cul-
tures if no respiratory sample was positive). The clinically
evaluable (CE) population consisted of patients in the AT
population who were protocol-adherent or who died on or after
study day 3, if death was attributable to the HAP episode under
study. The microbiologically evaluable (ME) population con-
sisted of CE patients who had a gram-positive respiratory
pathogen recovered from baseline respiratory specimens or
blood cultures. The safety population included patients who
received >1 dose of study medication.
Statistical analyses. The primary efﬁcacy end point of each
study was clinical response at FU/TOC in the AT and CE pop-
ulations. Failure at EOT was carried forward to FU/TOC. Two-
sided 95% conﬁdence intervals (CIs) were calculated on the
difference in response rate; pooled-study CIs were stratiﬁed on
study. The primary efﬁcacy end point was tested for the non-
inferiority of telavancin compared with vancomycin in both the
AT and CE populations in each study, using a prespeciﬁed non-
inferioritymargin of20%anda1-sidedsigniﬁcance levelof.025.
Assuming that 35% of enrolled patients would be in the CE
group and that cure rates would be 60% in both treatment
groups, 312 enrolled patients per treatment arm would provide
109 CE patients and statistical power of 86% to achieve non-
inferiority. A key prespeciﬁed secondary objective was to per-
form a 2-study pooled analysis of telavancin superiority
compared with vancomycin treatment in patients with pneu-
monia due to MRSA. Post hoc analyses of cure rates at FU/TOC
visit by baseline pathogen characteristics (methicillin resistance
status,vancomycinMIC,andevidenceformixedgram-negative/
gram-positive infection) were also performed; statistical in-
ferential statements are not adjusted for multiple comparisons.
Deaths through FU/TOC were summarized. If there was no
FU/TOC visit, any death reported to have occurred within 28
days after end of treatment was included in the analysis. Within
this article, results are presented from analysis of the pooled
datasets from the 2 studies. Primary efﬁcacy results are also
presented for each study separately.
RESULTS
Disposition of patients. A total of 1532 patients from 274
study sites in 38 countries were randomized (Figure 1). In all,
1503 patients received >1 dose of study medication (telavancin,
n 5 749; vancomycin, n 5 754; AT population). The most
common reasons for exclusion from the CE population were
indeterminate or missing responses at FU/TOC, receipt of po-
tentially effective nonstudy systemic antibiotics, and isolation of
only gram-negative bacteria (Figure 1). The most common
reasons for missing or indeterminate responses at FU/TOC were
patient death due to causes other than HAP and presence of
gram-negative pathogen only, respectively.
Baseline and demographic characteristics. Baseline and
demographic variables were comparable between treatment
groups (Table 1). Patients aged >65 years accounted for more
than one-half of those enrolled and treated in both treatment
groups. More thanone-half of the patients were in intensive care
units at baseline. Common co-morbidities included diabetes
mellitus, chronic obstructive pulmonary disease, and acute and/
or chronic renal failure. Almost two-thirds of patients had
multilobarinﬁltrates,andnearlyone-thirdhadpleuraleffusions.
Figure 1. Patient disposition for studies 0015 and 0019. Patients could
have .1 reason for exclusion from either the clinically evaluable (CE) or
microbiologically evaluable (ME) populations. *Among those randomized
to receive vancomycin, 20 patients had treatment switched to
antistaphylococcal penicillins, and 2 patients in study 0019 who were
randomized to receive vancomycin actually received telavancin. These 2
patients are included in the vancomycin group for the efficacy analysis
(all-treated population) but were included in the telavancin group for the
safety analysis. Because of this protocol deviation, neither patient was
included in the CE population.
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of the patients received antibiotic therapy for >24 h prior to
enrollment. Among these patients, the most common reasons
allowing enrollment were clinical failure despite prior antibiotic
therapy and development of pneumonia while receiving anti-
bacterials for other indications.
Table 1. Baseline and Demographic Characteristics for the Pooled Studies All-Treated Population
Characteristic Telavancin (n 5 749) Vancomycin (n 5 754) P
Age, mean years 6 SD 62 6 18.5 63 6 17.7 .40
Age >65 years 397 (53) 408 (54) .68
Female sex 262 (35) 285 (38) .26
Race .68
White 515 (69) 526 (70)
African American 25 (3) 20 (3)
Asian 172 (23) 178 (24)
Other 37 (5) 30 (4)
Diabetes 203 (27) 191 (25) .45
Congestive heart failure 130 (17) 141 (19) .50
COPD 173 (23) 178 (24) .86
Chronic renal failure 43 (6) 52 (7) .40
Acute renal failure 73 (10) 64 (8) .42
CrCL <50 mL/min 255 (34) 250 (33) .74
Hemodialysis 14 (2) 14 (2) 1.0
Admission to ICU 431 (58) 440 (58) .75
Use of vasopressor/inotropic 54 (7) 89 (12) .003
Shock 29 (4) 41 (5) .18
ARDS 33 (4) 30 (4) .70
ALI 51 (7) 33 (4) .04
APACHE II score, mean 6 SD
a 15 6 6.1 16 6 6.2 .11
APACHE II score >20 167 (22) 191 (25) .18
Bacteremia at onset
b 48 (6) 44 (6) .67
VAP 216 (29) 211 (28) .73
Signs of pneumonia
Fever (temperature .38C) 558 (74) 552 (73) .60
WBC count .10,000 cells/mm
3c 412 (65) 408 (65) .95
Purulent secretions 677 (90) 705 (94) .03
PaO2/FiO2, mean 6 SD
d 254 6 142 244 6 125 .69
Heart rate .120 beats/min 139 (19) 144 (19) .79
Respiratory rate .30 breaths/min 242 (32) 246 (33) .91
SIRS
e 624 (83) 632 (84) .84
Radiological characteristics
Multilobar inﬁltrates 473 (63) 460 (61) .40
Pleural effusion 237 (32) 244 (32) .78
Prior antibiotic use (.24 h) 391 (52) 427 (57) .09
Developed pneumonia while on
antibiotic treatment for other indication
189 (25) 208 (28) .94
Clinical failure of prior antibiotics 215 (29) 211 (28) .12
Resistant organisms 92 (12) 102 (14) .94
NOTE. Data are no. (%) of patients, unless otherwise indicated. ALI, acute lung injury [20]; APACHE, Acute Physiology and Chronic Health Evaluation; ARDS,
adult respiratory distress syndrome [21]; COPD, chronic obstructive pulmonary disease; CrCL, creatinine clearance; ICU, intensive care unit; SD, standard deviation;
SIRS, systemic inﬂammatory response syndrome; VAP, ventilator-associated pneumonia; WBC, white blood cells.
a Complete APACHE II scores (21) were available for 396 and 406 patients in the telavancin and vancomycin arms, respectively. For the remaining patients,
APACHE II scores were computed with the available data plus missing components imputed with a value of zero.
b Any respiratory pathogen recovered from baseline blood cultures.
c Denominator is based on patients with a baseline WBC count.
d Relates to patients receiving mechanical ventilation.
e Deﬁned as the presence of 2 or more of the following 4 criteria: (1) temperature .38Co r,36C; (2) heart rate .90 beats/min; (3) respiration .20 breaths/min
or PaCO2 ,32 mm Hg; (4) leukocyte count .12,000 cells/mm
3 or ,4000 cells/mm
3,o r.10% immature (band) cells.
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tum or endotracheal aspirates (particularly in intubated pa-
tients), with ,20% of patients undergoing more-invasive
procedures (Table 2). S. aureus was the most common gram-
positive pathogen isolated from the respiratory tract; the ma-
jority (60%) of S. aureus isolates were MRSA (Table 2). Mixed
infections (ie, infections due to gram-positive and gram-
negative pathogens) were present in 27% of patients. The most
common gram-negative pathogens were Pseudomonas aerugi-
nosa, Klebsiella pneumoniae,a n dAcinetobacter species.
The MIC90 for both MRSA and MSSA was .5 lg/mL
for telavancin and 1 lg/mL for vancomycin. The mean
(6 standard deviation [SD]) predose plasma concentration
(Ctrough) of telavancin for patients in the 2 studies were 10–12
lg/mL. Telavancin mean peak plasma concentration was 70
lg/mL. In those patients for whom .1 vancomycin serum
trough level was obtained (n 5 226), mean trough levels were
>5 lg/mL in 94% (n 5 212) and >10lg/mL in 66% (n 5 149)
of patients.
Primary outcome measures. Cure rates at FU/TOC in the 2
treatment groups were similar in each study (Table 3). Results
from studies 0015 and 0019 each met the criterion for non-
inferiority of telavancin compared with vancomycin. The 95%
CI for the treatment difference between the 2 regimens from
each study overlapped, supporting pooling of the data. Thus,
cure rates in the pooled AT population were 58.9% for tela-
vancin and 59.5% for vancomycin (95% CI for the difference,
–5.6% to 4.3%), whereas in the pooled CE patients, cure rates
were 82.4% for telavancin and 80.7% for vancomycin (95% CI
for the difference, –4.3% to 7.7%). The most commonly listed
reason for failure at FU/TOC in AT and CE patients in both
treatment groups was treatment failure at EOT (Table 4).
Secondary outcome measures. In patients with pneumonia
due to MRSA with or without other pathogens, the clinical re-
sponse at FU/TOC between the treatment groups was similar
(Table 5). Cure rates were higher in the telavancin group in
patients with monomicrobial infection due to S. aureus, and this
was consistent for both patients with MRSA and those with
MSSA. Telavancin cure rates were also higher in patients in-
fected with S. aureus that demonstrated a vancomycin MIC >1
lg/mL (Table 5). Lower cure rates in patients with mixed in-
fections were observed in the telavancin group. In patients with
mixed infections who received adequate gram-negative cover-
age, cure rates were similar between the 2 groups (Table 5).
Safety analysis. The overall incidence of AE was compa-
rable in the 2 groups (Table 6). For study 0015, 80 (21.5%) of
372 telavancin-treated patients died, and 62 (16.6%) of 374
vancomycin-treated patients died (95% CI for the difference,
–0.7% to 10.6%). For study 0019, 70 (18.5%) of 379 telavancin-
treatedpatients died, and 78(20.6%)of 378 vancomycin-treated
patients died (95% CI for the difference, –7.8% to 3.5%).
Most common treatment-emergent AEs (TEAEs) in both
treatment groups were diarrhea, anemia, hypokalemia, con-
stipation, and renal impairment (Table 6). The incidences of
serious AEs (SAEs) and TEAEs leading to discontinuation of
study medication were higher in the telavancin group (31% vs
26% and 8% vs 5%, respectively). The most common SAEs in
patients receiving telavancin and those receiving vancomycin
were septic shock (4% vs 4%), respiratory failure (3% vs 3%),
and multiorgan failure (3% vs 2%). The most frequently re-
ported AE leading to study medication discontinuation was
acute renal failure (1.2%) in telavancin-treated patients and
septic shock (0.7%) in vancomycin-treated patients.
Table 2. Microbiological Characteristics at Study Entry for the
Pooled Studies Microbiologically Evaluable Population
Characteristic
No. (%) of patients
Telavancin
(n 5 243)
Vancomycin
(n 5 237)
Respiratory tract samples
a
Sputum 96 (40) 115 (49)
Endotracheal aspiration 100 (41) 92 (39)
Invasive techniques
b 41 (17) 31 (13)
Other
c 3 (1) 4 (2)
Type of respiratory pathogen
d
Gram-positive only 175 (72) 174 (73)
Mixed (gram-positive
and gram-negative)
68 (28) 63 (27)
Respiratory samples
Staphylococcus aureus
e 215 (88) 213 (90)
MRSA 136 (56) 154 (65)
MSSA 83 (34) 61 (26)
Streptococcus pneumonia 20 (8) 21 (9)
Pseudomonas aeruginosa 34 (14) 22 (9)
Acinetobacter species 17 (7) 13 (5)
Klebsiella pneumoniae 11 (5) 20 (8)
Other gram-negative
organisms
24 (10) 19 (8)
Blood
d
S. aureus 14 (6) 9 (4)
MRSA 9 (4) 6 (3)
MSSA 5 (2) 3 (1)
Gram-negative pathogens 1 (,1) 6 (3)
NOTE. MRSA, methicillin-resistant S. aureus; MSSA, methicillin-suscep-
tible S. aureus.
a Percentages do not add to 100% because a small proportion of patients
did not have a respiratory sample taken (telavancin group) or had .1 sampling
method (vancomycin group).
b Invasive techniques included bronchoalveolar lavage (BAL), mini-BAL, and
blind bronchial suctioning.
c Other methods were speciﬁed as quantitative tracheal lavage and
protected specimen brush.
d Includes 4 patients in the telavancin group and 1 patient in the vancomycin
group with pathogens isolated exclusively from blood cultures.
e Includes 4 patients in the telavancin group and 2 patients in the
vancomycin group with both MRSA and MSSA.
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levels (.50% increase from baseline and a maximum value
.1.5 mg/dL) were more common in the telavancin group than
in the vancomycin group (16% vs 10%). Other than creatinine
level increases, the most common abnormalities in both treat-
ment groupswere anemia, abnormal serum potassium levels, and
hepatic enzyme abnormalities (Table 7). All of these abnormal-
ities occurred with similar frequencies in the 2 treatment groups.
Prolongation of Fridericia-corrected QT interval (QTcF) by
.60 msec occurred in 8% and 7% of the telavancin-treated and
vancomycin-treated patients, respectively. A maximum QTcF
interval value .500 msec occurred in a similar proportion of
patients (2%) in the 2 groups. None of the patients experienced
arrhythmias attributable to a prolonged QTcF interval.
DISCUSSION
The results of the ATTAIN trials reported herein demonstrate
that telavancin has clinical response outcomes that are non-
inferior to those of vancomycin in the treatmentof patients with
HAP due tothegram-positivebacteria, such as S.aureus (MRSA
and MSSA) and S. pneumoniae. Importantly, these ﬁndings,
which incorporate data for more than 1500 patients from .250
sites around the world, are robust and consistent across all ef-
ﬁcacy populations.
The ATTAIN trials, which enrolled almost 300 ME patients
with monomicrobial S. aureus pneumonia, demonstrated that
telavancin therapy achieved higher cure rates than did vanco-
mycin therapy in the group of patients with pneumonia due to
S. aureus. Higher cure rates were also observed in the telavancin
group among patients infected with S. aureus that had a vanco-
mycin MIC >1m g / L .
Importantly, telavancin was effective in the treatment of pa-
tients with pneumonia due to MRSA, as well as in the treatment
of those patients with pneumonia due to MSSA. The high cure
rates obtained in the telavancin group support the use of tela-
vancin as empirical therapy for suspected S. aureus pneumonia
as well as its use as targeted therapy for both MRSA and MSSA
infections.
Alowercureratewasassociatedwithtelavancintherapyinthe
subgroup of patients with mixed infections, although the dif-
ference was not statistically signiﬁcant. Because telavancin has
Table 4. Reasons for Treatment Failure at Follow-up/Test-of-Cure Visit for Pooled Studies
Variable
Telavancin,% (proportion) of patients Vancomycin,
a % (proportion) of patients
AT group CE group AT group CE group
Failure at EOT 11.1 (83/749) 15.7 (49/312) 13.5 (102/754) 17.3 (59/342)
Death on or after day
3 attributable to HAP
3.1 (23/749) 5.4 (17/312) 2.1 (16/754) 3.5 (12/342)
Death after EOT
attributable to HAP
0.7 (5/749) 0.3 (1/312) 0.1 (1/754) 0.0 (0/342)
Relapsed pneumonia 1.3 (10/749) 1.3 (4/312) 2.1 (16/754) 2.0 (7/342)
Total 13.2 (99/749) 17.6 (55/312) 15.9 (120/754) 19.3 (66/342)
NOTE. AT, all-treated population; CE, clinically evaluable population; EOT, end of treatment; HAP, hospital-acquired pneumonia.
a Includes 6 patients who received antistaphylococcal penicillin instead of vancomycin.
Table 3. Cure Rates for Hospital-Acquired Pneumonia at Follow-up/Test-of-Cure Visit
Study, analysis
population
Telavancin group,%
(proportion) of patients
Vancomycin group,
a%
(proportion) of patients
Treatment difference,%
of patients (95% CI)
Study 0015
AT 57.5 (214/372) 59.1 (221/374) 21.6 (–8.6 to 5.5)
CE 83.7 (118/141) 80.2 (138/172) 3.5 (–5.1 to 12.0)
Study 0019
AT 60.2 (227/377) 60.0 (228/380) 0.2 (–6.8 to 7.2)
CE 81.3 (139/171) 81.2 (138/170) 0.1 (–8.2 to 8.4)
Pooled data
AT 58.9 (441/749) 59.5 (449/754) 20.7 (–5.6 to 4.3)
CE 82.4 (257/312) 80.7 (276/342) 1.7 (–4.3 to 7.7)
ME 79.0 (192/243) 76.8 (182/237) 2.2 (–5.2 to 9.7)
NOTE. AT, all-treated population; CE, clinically evaluable population; CI, conﬁdence interval; ME, microbiologically evaluable population.
a Includes 20 AT patients and 6 CE patients who received antistaphylococcal penicillins instead of vancomycin.
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could be a result of inadequate gram-negative therapy. This is
supported by the ﬁnding that, in the subset of patients with
mixed infections who received adequate gram-negative cover-
age, cure rates were similar in the 2 treatment groups.
Although more patients in the telavancin group experienced
SAEs or had treatment discontinued due to an AE, compared
with patients in the vancomycin group, the incidences of most
common AEs were similar in the 2 treatment groups. Clinically
signiﬁcant increases in serum creatinine level were more frequent
among telavancin-treated patients. In the majority of patients in
both groups with signiﬁcant creatinine increases, the impairment
in renal function had resolved or was resolving at the last follow-
up visit. The numbers of patients with QTcF interval pro-
longation .60 msec or those with absolute QTcF interval .500
msecwere comparable between the treatment groups. Death rates
were higher for telavancin-treated patients than they were for
vancomycin-treated patients in study 0015, whereas the opposite
trend was seen in study 0019. Although the ATTAIN trials were
not optimally designed for a mortality end point, the differences
observed in these studies were not statistically signiﬁcant.
The strengths of the ATTAIN trials should be underscored.
First, when the ATTAIN trials were conducted, the combined
populations of these identically designed trials provided, to
our knowledge, the largest cohort of patients studied to date
for HAP. Similarly, to date, the S. aureus and MRSA subgroups
are the largest such subgroups available of patients with HAP.
Third, the breadth and diversity of the patient population
make the results generalizable to many settings. Lastly, a sig-
niﬁcant proportion of patients enrolled in these studies were
critically ill.
These studies also have limitations. First, the standard of care
in much of the world for diagnosis of HAP does not include
semi-invasive diagnostic procedures (eg, bronchoalveolar la-
vage), and the limited number of patients who underwent these
procedures makes determination of the exact etiology of HAP
potentially less reliable than would otherwise be the case.
However, the noninvasive diagnostic techniques used in these
studiesfollowed the guidelines of the American Thoracic Society
and the Infectious Diseases Society of America [9] and are
supported by a large ventilator-associated pneumonia study that
demonstratedsimilaroutcomesforpatientsundergoinginvasive
or noninvasive diagnostic approaches [22]. Second, our com-
parator antibiotic (vancomycin) has been cited as potentially
inferior to linezolid for patients with MRSA pneumonia.
However, the results of the post hoc analysis of 2 previous
studies of linezolid versus vancomycin are controversial [23]. As
a result, vancomycin continues to be commonly used to treat
patients with HAP in whom MRSA infection is suspected or
identiﬁed [24]. Third, the vancomycin dosage was adjusted in
accordance with institutional policies. Although such policies
differed between sites, they reﬂect the real use of vancomycin
Table 5. Cure Rates at Follow-up/Test-of-Cure Visit by Baseline Pathogen for the Pooled Microbiologically Evaluable Population
Infection type
Telavancin,% (proportion)
of patients
Vancomycin,
a % (proportion)
of patients
Treatment difference,% of
patients (95% CI)
All Staphylococcus aureus
b 78.1 (171/219) 75.2 (161/214) 3.0 (–5.0 to 11.0)
All MRSA
c 74.8 (104/139) 74.7 (115/154) 0.4 (–9.5 to 10.4)
Monomicrobial S. aureus 84.2 (123/146) 74.3 (113/152) 9.9 (0.7 to 19.1)
Vancomycin MIC <0.5 lg/mL
d 89.2 (33/37) 78.6 (22/28) 10.1 (29.0 to 28.8)
Vancomycin MIC >1 lg/mL
e 87.1 (74/85) 74.3 (78/105) 12.5 (0.5 to 23.0)
f
MRSA 81.8 (72/88) 74.1 (86/116) 7.9 (–3.5 to 19.3)
MSSA 87.9 (51/58) 75.0 (27/36) 12.2 (–4.2 to 28.8)
Streptococcus pneumoniae 90.0 (18/20) 85.7 (18/21) 5.9 (–19.1 to 29.7)
Mixed infections
g 66.2 (45/68) 79.4 (50/63) –12.6 (–26.9 to 3.2)
Mixed infections with adequate
gram-negative therapy
h
63.2 (12/19) 66.7 (14/21) –0.8 (–28.9 to 25.7)
NOTE. CI, conﬁdence interval; MIC, vancomycin minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S.
aureus.
a Includes 5 microbiologically evaluable patients who received antistaphylococcal penicillins instead of vancomycin.
b S. aureus with and without concomitant pathogens; includes 4 patients in the telavancin group and 1 patient in the vancomycin group with pathogens isolated
exclusively from blood cultures.
c MRSA with and without concomitant pathogens.
d All vancomycin MICs 5 0.5 lg/mL, except for 1 patient in the telavancin group with MIC <0.25 lg/mL.
e All vancomycin MICs 5 1.0 lg/mL, except for 2 patients in the telavancin group with MIC 5 2.0 lg/mL.
f P 5 .03.
g Mixed gram-positive and gram-negative infections.
h Inadequate gram-negative coverage was deﬁned as not having received an antibiotic to which the recovered gram-negative pathogen was susceptible until
study day 3 or later or not receiving such an antibiotic at all during study treatment.
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Despite the unresolved controversy regarding the clinical value
of determiningserum levelsofvancomycin, the large majorityof
patients for whom vancomycin levels were obtained had mean
trough levels that were considered ‘‘adequate’’ (ie, 5–15 lg/mL)
at the time the studies were conducted. Baseline renal status, as
well as co-morbidities known to predispose patients to renal
dysfunction, should be taken into consideration before treat-
ment is initiated. Renal function should be monitored in all
patients receiving telavancin.
In summary, the 2 large identically designed, double-blinded,
randomized ATTAIN trials demonstrate that telavancin is
effective in the treatment of patients with HAP caused by
gram-positive pathogens. In the overall population, telavancin
has an acceptable risk proﬁle for the treatment of patients
with HAP.
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Table 6. SafetyparametersforthePooledStudiesSafetyPopulation
No. (%) of patients
Safety parameter
Telavancin
group (n 5 751)
Vancomycin
group
a (n 5 752)
Death
b 150 (20.0) 140 (18.6)
Any TEAE 616 (82) 613 (82)
Any serious AE 234 (31) 197 (26)
Discontinued medication
due to TEAE
60 (8) 40 (5)
TEAE >5% in any treatment arm
Diarrhea 85 (11) 92 (12)
Renal impairment
c 74 (10) 57 (8)
Anemia 64 (9) 85 (11)
Constipation 70 (9) 71 (9)
Hypokalemia 61 (8) 80 (11)
Hypotension 48 (6) 52 (7)
Nausea 40 (5) 31 (4)
Decubitus ulcer 39 (5) 44 (6)
Insomnia 34 (5) 47 (6)
Peripheral edema 34 (5) 38 (5)
NOTE. AE, adverse event; TEAE, treatment-emergent adverse event.
a Includes 20 patients who received antistaphylococcal penicillin instead of
vancomycin and 2 patients randomized to vancomycin who actually received
telavancin.
b Point estimate (95% conﬁdence interval) on the treatment difference
(telavancin minus vancomycin) in death rate, –1.4% (–2.6% to 5.3%).
c Includes renal impairment, renal insufﬁciency, acute renal failure, chronic
renal failure, and creatinine level increase.
Table 7. Laboratory Abnormalities in Patients with Normal
Values at Baseline for the Pooled Studies Safety Population
Variable
Proportion (%) of patients
Telavancin
group
Vancomycin
group
Hematocrit
Male sex, <30% 13/99 (13) 17/106 (16)
Female sex, <28% 15/97 (15) 16/93 (17)
WBC count ,2800 cells/lL 1/251 (,1) 6/243 (2)
Platelet count <75,000 platelets/lL 6/370 (2) 10/403 (2)
AST level >3 ULN 23/359 (6) 17/358 (5)
ALT level >3 ULN 22/398 (6) 33/411 (8)
Alkaline phosphatase
level >2 ULN
23/469 (5) 40/505 (8)
Potassium level ,3 meq/L 50/587 (9) 37/579 (6)
Potassium level .5.5 meq/L 33/587 (6) 32/579 (6)
Creatinine level increase
a 111/716 (16) 69/723 (10)
NOTE. ALT, alanine aminotransferase; AST, aspartate aminotransferase;
ULN, upper limit of normal; WBC, white blood cell.
a Serum creatinine level increased .50% from baseline and with
a maximum value .1.5 mg/dL regardless of the initial value; includes patients
with abnormal serum creatinine levels at baseline.
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